Sweden
SynAct Pharma is a biotech company based in Sweden, founded in 2012, with a focus on resolving inflammation through melanocortin biology. Their lead asset, AP1189, is currently in phase 2 development for the treatment of rheumatoid arthritis. The drug is an immunomodulatory small molecule delivered as a once-daily tablet, acting as a selective melanocortin receptor type 1 and 3 agonist, making it a first-in-class solution. The company reported very promising efficacy and safety results from the Phase 2a BEGIN study in patients with rheumatoid arthritis in November 2021, and the next step is to open an IND with FDA to seek advice on further development. Additionally, due to its known mode of action, AP1189 was also tested in COVID-19 positive patients, with results in July 2021 showing significant improvements in respiratory recovery, hospital discharge, and reduced risk of progressing to needing mechanical ventilation.
The company received its last investment of €71.43K in the form of a grant investment on 01 May 2018 from EASME - EU Executive Agency for SMEs. SynAct Pharma operates within the Biotechnology and Health Care industries and is making strides in pioneering treatments for inflammatory conditions, positioning it as a promising prospect in the biotech space.
